AUS
NZ
UK
CA
USA
IND
Highlights
- Healius sells Lumos Imaging to Affinity Equity Partners for $965m.
- Sigma Healthcare awaits ACCC decision on Chemist Warehouse merger.
- Percheron Therapeutics advances Phase 2B trial for Duchenne muscular dystrophy.
This week, the healthcare sector witnessed significant updates across several companies, driving market attention. Healius Ltd (ASX:HLS), a major player in pathology, made headlines by announcing the sale of its Lumos Imaging (radiology) arm to Affinity Equity Partners for an enterprise value of $965 million. This transaction is expected to be finalized by Q1 of the 2025 calendar year and is seen as a positive move for Healius. The company is set to streamline operations by focusing on its core pathology business, which should also bolster its balance sheet and reduce corporate costs.
Healius, an ASX healthcare stock, has historically held a collection of diverse businesses including IVF, day hospitals, GP practices, and radiology. This divestment marks a return to the company's primary strength in pathology. Market analysts have noted that Healius is likely to use the proceeds in a tax-efficient manner, though specifics remain undisclosed.
Sigma Healthcare's Anticipated Merger Decision
Sigma Healthcare Ltd (ASX:SIG) is also in the spotlight as it awaits the Australian Competition and Consumer Commission (ACCC) ruling on its proposed merger with Chemist Warehouse. The decision is expected by October 24, 2024. Earlier this year, Sigma secured a $2 billion per annum supply contract for PBS medicines to Chemist Warehouse, replacing EBOS Group (ASX:EBO).
Sigma's H1 FY25 results showed a 9.4% increase in sales, reaching $1.8 billion. This includes one month of revenue from the new Chemist Warehouse supply contract. Analysts have pointed out the potential for Sigma to gain cost synergies from this merger, which would strengthen its position in Australia's pharmaceutical retail sector.
Percheron Therapeutics' Key Milestone
In biotech news, Percheron Therapeutics Ltd (ASX:PER) continues to make progress with its Phase 2B trial for avicursen (ATL1102), a promising therapy for Duchenne muscular dystrophy (DMD). The trial is focused on non-ambulant boys with DMD, and the results are expected by the end of the 2025 calendar year. Avicursen, an antisense oligonucleotide targeting CD49d, has already shown effectiveness in treating multiple inflammatory conditions, including multiple sclerosis and DMD.
If the trial proves successful, Percheron Therapeutics could experience a significant revaluation of its share price, along with potential licensing deals, positioning it as a major player in the rare diseases market.
Healthcare Market Outlook
As of 11am AEST on Friday, the S&P/ASX 200 Health Care index (ASX:XHJ) was down 0.2% over the past five days, while the broader S&P/ASX 200 (ASX:XJO) index posted a 0.2% gain. Despite this slight downturn in healthcare stocks, there is optimism in the market fueled by recent developments in the U.S. Federal Reserve’s interest rate cuts and improved economic data from China. Investors are looking towards sectors with growth potential, and the healthcare industry remains one to watch.
Capital Raisings on the Rise
Lastly, capital raising activity is picking up, with cardiac-focused EBR Systems Ltd (ASX:EBR) recently announcing a fully underwritten institutional placement to raise $50 million. This signals increasing appetite among investors for healthcare stocks as the sector continues to show resilience and innovation.
Healthcare companies like Healius, Sigma, and Percheron are making strategic moves that could reshape their futures. As developments unfold, market watchers will keep a close eye on how these shifts influence both individual stocks and the broader healthcare sector.
